Anne Le
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Anne Le has a total of 540 co-authors. Here are the top co-authors by number of shared publications:
Cissy Zhang
Department of Pathology Johns Hopkins University School of Medicine Baltimore MD 21205 USA
14 shared publications- Chi Van Dang
Graduate Program in Cellular and Molecular Medicine, Johns Hopkins University School of Medicine, Baltimore, USA
13 shared publications Jin G. Jung
Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA
6 shared publicationsAddison Quinones
Icahn School of Medicine at Mount Sinai, New York, NY, USA
5 shared publicationsBrad Poore
Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD 21205
5 shared publicationsGiang Hoang
Department of Pathology Johns Hopkins University School of Medicine Baltimore MD 21205 USA
5 shared publications
Latest Publications
- Open Access
- 10 September 2026
- Published by Wiley in Aging Cell
- Vol. 25 (9)
Sustained Activation of CaMKII Promotes Skeletal Muscle Contractile Dysfunction in Aging
Sarcopenia, the age‐related loss of muscle strength and mass, contributes to adverse health outcomes in older adults. Exercise engages calcium (Ca 2+ )‐ and redox‐dependent signaling pathways that enhance muscle performance and adaptation, whereas aging disrupts Ca 2+ and redox homeostasis. CaMKII is a key transducer of both signals, raising the possibility that sustained CaMKII signaling becomes maladaptive with aging. Here, we show that CaMKII protein abundance is increased in aged mouse skeletal muscle and that sustained CaMKII activation in young muscle is sufficient to impair contractile function before substantial atrophy develops and, with prolonged activation, to promote progressive muscle loss. Sustained CaMKII activation also disrupted mitochondrial organization and shifted the young‐muscle transcriptome toward an aged profile characterized by inflammatory and stress‐response pathways. Inhibiting canonical NF‐κB signaling partially preserved contractile force during prolonged CaMKII activation without preserving muscle mass, and mediation analysis implicated heme/iron‐related transcriptional remodeling in the muscle‐mass‐independent decline in force. Conversely, expression of CN19o, a peptide inhibitor of CaMKII, in aged muscle improved contractile function and shifted the transcriptome away from an aging‐associated profile without inducing hypertrophy. Together, these findings identify sustained CaMKII signaling as a contributor to age‐associated muscle dysfunction and support a context‐dependent shift from adaptive CaMKII signaling in youth to maladaptive signaling in aging, consistent with antagonistic pleiotropy.
- 10 September 2026
- Published by Wiley in Aging Cell
- Vol. 25 (9)
Open AccessSustained Activation of CaMKII Promotes Skeletal Muscle Contractile Dysfunction in Aging
Sarcopenia, the age‐related loss of muscle strength and mass, contributes to adverse health outcomes in older adults. Exercise engages calcium (Ca 2+ )‐ and redox‐dependent signaling pathways that enhance muscle performance and adaptation, whereas aging disrupts Ca 2+ and redox homeostasis. CaMKII is a key transducer of both signals, raising the possibility that sustained CaMKII signaling becomes maladaptive with aging. Here, we show that CaMKII protein abundance is increased in aged mouse skeletal muscle and that sustained CaMKII activation in young muscle is sufficient to impair contractile function before substantial atrophy develops and, with prolonged activation, to promote progressive muscle loss. Sustained CaMKII activation also disrupted mitochondrial organization and shifted the young‐muscle transcriptome toward an aged profile characterized by inflammatory and stress‐response pathways. Inhibiting canonical NF‐κB signaling partially preserved contractile force during prolonged CaMKII activation without preserving muscle mass, and mediation analysis implicated heme/iron‐related transcriptional remodeling in the muscle‐mass‐independent decline in force. Conversely, expression of CN19o, a peptide inhibitor of CaMKII, in aged muscle improved contractile function and shifted the transcriptome away from an aging‐associated profile without inducing hypertrophy. Together, these findings identify sustained CaMKII signaling as a contributor to age‐associated muscle dysfunction and support a context‐dependent shift from adaptive CaMKII signaling in youth to maladaptive signaling in aging, consistent with antagonistic pleiotropy.
- Open Access
- 1 April 2025
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 14 (7) , e038061
Methylated Arginine Metabolites as Biomarkers for Clinical Status and Response to Type 5 Phosphodiesterase Inhibition in Patients With Fontan Circulation
Background: There is significant interest in NO pathway modulators, specifically type 5 phosphodiesterase inhibitors (PDE5is), to treat patients with a Fontan circulation. Trials, however, have had mixed results. The relationship between the NO pathway and clinical status in patients with Fontan circulation is a significant knowledge gap. Methods and Results: We performed targeted metabolomic analysis using liquid chromatography coupled to mass spectrometry to quantify plasma NO pathway metabolite concentrations from 2 well‐characterized populations of patients with Fontan circulation: the Boston Adult Congenital Heart Disease Biobank and Fontan Udenafil Exercise Longitudinal studies. We investigated associations between NO metabolite concentrations and clinical outcomes, exercise capacity, and response to PDE5is. Increased plasma concentration of asymmetric dimethyl arginine (ADMA), an inhibitor of NO production, was associated with risk for hospitalization or death. Increased ADMA and symmetric dimethyl arginine (another inhibitor of NO production) concentrations were associated with decreased baseline exercise capacity among patients with Fontan circulation with <90% predicted peak oxygen uptake, and change in ADMA and symmetric dimethyl arginine concentrations were predictive of change in exercise capacity over time. Treatment with the PDE5i udenafil uncoupled this association. Finally, baseline ADMA and symmetric dimethyl arginine concentrations predicted response to PDE5is among patients with subnormal peak oxygen uptake. Conclusions: Plasma concentrations of metabolites that inhibit NO flux are associated with negative clinical outcomes and worse exercise capacity. Moreover, metabolite shifts over time associated with increased NO flux are associated with improved exercise capacity. In patients with a Fontan circulation, the NO pathway modulators ADMA and symmetric dimethyl arginine may be useful as biomarkers of clinical status and predictive of response to PDE5is.
- 1 April 2025
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 14 (7) , e038061
Open AccessMethylated Arginine Metabolites as Biomarkers for Clinical Status and Response to Type 5 Phosphodiesterase Inhibition in Patients With Fontan Circulation
Background: There is significant interest in NO pathway modulators, specifically type 5 phosphodiesterase inhibitors (PDE5is), to treat patients with a Fontan circulation. Trials, however, have had mixed results. The relationship between the NO pathway and clinical status in patients with Fontan circulation is a significant knowledge gap. Methods and Results: We performed targeted metabolomic analysis using liquid chromatography coupled to mass spectrometry to quantify plasma NO pathway metabolite concentrations from 2 well‐characterized populations of patients with Fontan circulation: the Boston Adult Congenital Heart Disease Biobank and Fontan Udenafil Exercise Longitudinal studies. We investigated associations between NO metabolite concentrations and clinical outcomes, exercise capacity, and response to PDE5is. Increased plasma concentration of asymmetric dimethyl arginine (ADMA), an inhibitor of NO production, was associated with risk for hospitalization or death. Increased ADMA and symmetric dimethyl arginine (another inhibitor of NO production) concentrations were associated with decreased baseline exercise capacity among patients with Fontan circulation with <90% predicted peak oxygen uptake, and change in ADMA and symmetric dimethyl arginine concentrations were predictive of change in exercise capacity over time. Treatment with the PDE5i udenafil uncoupled this association. Finally, baseline ADMA and symmetric dimethyl arginine concentrations predicted response to PDE5is among patients with subnormal peak oxygen uptake. Conclusions: Plasma concentrations of metabolites that inhibit NO flux are associated with negative clinical outcomes and worse exercise capacity. Moreover, metabolite shifts over time associated with increased NO flux are associated with improved exercise capacity. In patients with a Fontan circulation, the NO pathway modulators ADMA and symmetric dimethyl arginine may be useful as biomarkers of clinical status and predictive of response to PDE5is.
- 4 March 2024
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 144 (9) , 2085-2089.e1
Excoriation Disorder Is Characterized by Systemic Glutamatergic Dysfunction
- 4 March 2024
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 144 (9) , 2085-2089.e1
Excoriation Disorder Is Characterized by Systemic Glutamatergic Dysfunction
- Open Access
- 23 November 2022
- Published by Wiley in Advanced Biology
- Vol. 7 (2) , e2200233
Metabolic Recycling Enhances Proliferation in MYC‐Transformed Lymphoma B Cells
Relapses negatively impact cancer patient survival due to the tumorigenesis ability of surviving cancer cells post‐therapy. Efforts are needed to better understand and combat this problem. This study hypothesized that dead cell debris post‐radiation therapy creates an advantageous microenvironment rich in metabolic materials promoting the growth of remaining live cancer cells. In this study, live cancer cells are co‐cultured with dead cancer cells eradicated by UV radiation to mimic a post‐therapy environment. Isotopic labeling metabolomics is used to investigate the metabolic behavior of cancer cells grown in a post‐radiation‐therapy environment. It is found that post‐UV‐eradicated dead cancer cells serve as nutritional sources of “off‐the‐shelf” and precursor metabolites for surviving cancer cells. The surviving cancer cells then take up these metabolites, integrate and upregulate multiple vital metabolic processes, thereby significantly increasing growth in vitro and probably in vivo beyond their intrinsic fast‐growing characteristics. Importantly, this active metabolite uptake behavior is only observed in oncogenic but not in non‐oncogenic cells, presenting opportunities for therapeutic approaches to interrupt the active uptake process of oncogenic cells without affecting normal cells. The process by which living cancer cells re‐use vital metabolites released by dead cancer cells post‐therapy is coined in this study as “metabolic recycling” of oncogenic cells.
- 23 November 2022
- Published by Wiley in Advanced Biology
- Vol. 7 (2) , e2200233
Open AccessMetabolic Recycling Enhances Proliferation in MYC‐Transformed Lymphoma B Cells
Relapses negatively impact cancer patient survival due to the tumorigenesis ability of surviving cancer cells post‐therapy. Efforts are needed to better understand and combat this problem. This study hypothesized that dead cell debris post‐radiation therapy creates an advantageous microenvironment rich in metabolic materials promoting the growth of remaining live cancer cells. In this study, live cancer cells are co‐cultured with dead cancer cells eradicated by UV radiation to mimic a post‐therapy environment. Isotopic labeling metabolomics is used to investigate the metabolic behavior of cancer cells grown in a post‐radiation‐therapy environment. It is found that post‐UV‐eradicated dead cancer cells serve as nutritional sources of “off‐the‐shelf” and precursor metabolites for surviving cancer cells. The surviving cancer cells then take up these metabolites, integrate and upregulate multiple vital metabolic processes, thereby significantly increasing growth in vitro and probably in vivo beyond their intrinsic fast‐growing characteristics. Importantly, this active metabolite uptake behavior is only observed in oncogenic but not in non‐oncogenic cells, presenting opportunities for therapeutic approaches to interrupt the active uptake process of oncogenic cells without affecting normal cells. The process by which living cancer cells re‐use vital metabolites released by dead cancer cells post‐therapy is coined in this study as “metabolic recycling” of oncogenic cells.
- Open Access
- 4 April 2022
- Published by Elsevier in Seminars in Cancer Biology
- Vol. 86 (Pt 3) , 180-188
Metabolic reservoir cycles in cancer
- 4 April 2022
- Published by Elsevier in Seminars in Cancer Biology
- Vol. 86 (Pt 3) , 180-188
Open AccessMetabolic reservoir cycles in cancer
- 23 November 2021
- Published by Oxford University Press (OUP) in The Journals of Gerontology, Series A: Biological Sciences and Medical Sciences
- Vol. 77 (12) , 2367-2372
Metabolomics-Based Identification of Metabolic Dysfunction in Frailty
Dysregulation of energy producing metabolic pathways has been observed in older adults with frailty. In this study, we used liquid chromatography–mass spectrometry technology to identify aging- and frailty-related differences in metabolites involved in glycolysis, the tricarboxylic (TCA) cycle, and other energy metabolism-related pathways in the serum of a cohort of community-dwelling adults aged 20–97 (n = 146). We also examined the relationship between serum levels of metabolites and functional measures, physical frailty, and risk status for adverse health outcomes. We observed elevated levels of TCA cycle and glycolytic intermediates in frail subjects; however, the differences in the levels of ATP and other energy metabolites between young, nonfrail, and frail adults were not significant. Instead, we found that serum levels of neurotransmitters N-acetyl-aspartyl-glutamate, glutamate, and γ-aminobutyric acid were significantly elevated in older adults with frailty. These elevations of glycolytic and TCA cycle intermediates, and neurotransmitters may be part of the biological signature of frailty.
- 23 November 2021
- Published by Oxford University Press (OUP) in The Journals of Gerontology, Series A: Biological Sciences and Medical Sciences
- Vol. 77 (12) , 2367-2372
Metabolomics-Based Identification of Metabolic Dysfunction in Frailty
Dysregulation of energy producing metabolic pathways has been observed in older adults with frailty. In this study, we used liquid chromatography–mass spectrometry technology to identify aging- and frailty-related differences in metabolites involved in glycolysis, the tricarboxylic (TCA) cycle, and other energy metabolism-related pathways in the serum of a cohort of community-dwelling adults aged 20–97 (n = 146). We also examined the relationship between serum levels of metabolites and functional measures, physical frailty, and risk status for adverse health outcomes. We observed elevated levels of TCA cycle and glycolytic intermediates in frail subjects; however, the differences in the levels of ATP and other energy metabolites between young, nonfrail, and frail adults were not significant. Instead, we found that serum levels of neurotransmitters N-acetyl-aspartyl-glutamate, glutamate, and γ-aminobutyric acid were significantly elevated in older adults with frailty. These elevations of glycolytic and TCA cycle intermediates, and neurotransmitters may be part of the biological signature of frailty.
- Open Access
- 1 November 2021
- Published by Elsevier in Analytical Biochemistry
- Vol. 632, 114206
Uncovering metabolic reservoir cycles in MYC-transformed lymphoma B cells using stable isotope resolved metabolomics
- 1 November 2021
- Published by Elsevier in Analytical Biochemistry
- Vol. 632, 114206
Open AccessUncovering metabolic reservoir cycles in MYC-transformed lymphoma B cells using stable isotope resolved metabolomics
- Open Access
- 22 October 2021
- Published by Springer Nature
- p. C1-C2
Correction to: The Heterogeneity of Cancer Metabolism
After initial publication of the book, various errors were identified that needed correction. All corrections listed below have been updated within the current version.
- 22 October 2021
- Published by Springer Nature
- p. C1-C2
Open AccessCorrection to: The Heterogeneity of Cancer Metabolism
After initial publication of the book, various errors were identified that needed correction. All corrections listed below have been updated within the current version.
- Open Access
- 1 October 2021
- Published by Elsevier in Current Opinion in Biotechnology
- Vol. 71, 115-122
The limitless applications of single-cell metabolomics
- 1 October 2021
- Published by Elsevier in Current Opinion in Biotechnology
- Vol. 71, 115-122
Open AccessThe limitless applications of single-cell metabolomics
- Open Access
- 1 September 2021
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 297 (3) , 101005
Diverse mitochondrial abnormalities in a new cellular model of TAFFAZZIN deficiency are remediated by cardiolipin-interacting small molecules
- 1 September 2021
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 297 (3) , 101005
Open AccessDiverse mitochondrial abnormalities in a new cellular model of TAFFAZZIN deficiency are remediated by cardiolipin-interacting small molecules